- $541.79m
- $568.63m
- $170.44m
Regenxbio's Duchenne gene therapy shows improved muscle function in trial
U.S. STOCKS ON THE MOVE-Hewlett Packard Enterprise, Dianthus, 3D Systems
Live Markets: Prasad's exit a win for biotechs, but don't celebrate yet
U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow
Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway
U.S. STOCKS ON THE MOVE -Erasca Inc, Regenxbio, Natgas stocks
Regenxbio falls as Q4 loss widens
Regenxbio Q4 revenue rises but loss widens as costs increase
Brief: Regenxbio Q4 License & Royalty Revenue USD 27.148 Million
US court revives Regenxbio patent lawsuit over muscular dystrophy treatment
U.S. STOCKS ON THE MOVE-Target, Warner Bros Discovery , Copper miners
U.S. STOCKS ON THE MOVE-Zimmer Biomet, Datadog, Ecolab
U.S. STOCKS ON THE MOVE-Vistra Corp, Quest Diagnostics, Jacobs Solutions
U.S. STOCKS ON THE MOVE-Spotify, DuPont, Hasbro
Regenxbio drops after FDA rejects gene therapy for rare disease
U.S. RESEARCH ROUNDUP-KKR, Sirius XM, Workday
Regenxbio falls after FDA rejects rare disease therapy
Brief: REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II
NASDAQ RESUMED AT 04:40 PM